ES2630037T3 - Suspensión farmacéutica - Google Patents

Suspensión farmacéutica Download PDF

Info

Publication number
ES2630037T3
ES2630037T3 ES09768284.3T ES09768284T ES2630037T3 ES 2630037 T3 ES2630037 T3 ES 2630037T3 ES 09768284 T ES09768284 T ES 09768284T ES 2630037 T3 ES2630037 T3 ES 2630037T3
Authority
ES
Spain
Prior art keywords
sediment
volume
molecular weight
peg
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09768284.3T
Other languages
English (en)
Spanish (es)
Inventor
Bhagwati P. Kabra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2630037T3 publication Critical patent/ES2630037T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09768284.3T 2008-12-05 2009-12-03 Suspensión farmacéutica Active ES2630037T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12008108P 2008-12-05 2008-12-05
US120081P 2008-12-05
PCT/US2009/066570 WO2010065730A2 (en) 2008-12-05 2009-12-03 Pharmaceutical suspension

Publications (1)

Publication Number Publication Date
ES2630037T3 true ES2630037T3 (es) 2017-08-17

Family

ID=41562672

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09768284.3T Active ES2630037T3 (es) 2008-12-05 2009-12-03 Suspensión farmacéutica

Country Status (17)

Country Link
US (1) US9707173B2 (pl)
EP (1) EP2364137B1 (pl)
JP (1) JP5661640B2 (pl)
AR (1) AR074423A1 (pl)
AU (1) AU2009322355B2 (pl)
CA (1) CA2745123C (pl)
CY (1) CY1119038T1 (pl)
DK (1) DK2364137T3 (pl)
ES (1) ES2630037T3 (pl)
HR (1) HRP20170959T1 (pl)
HU (1) HUE034662T2 (pl)
LT (1) LT2364137T (pl)
PL (1) PL2364137T3 (pl)
PT (1) PT2364137T (pl)
SI (1) SI2364137T1 (pl)
TW (1) TW201023912A (pl)
WO (1) WO2010065730A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101989A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
BRPI1008920A2 (pt) * 2009-03-03 2015-08-25 Alcon Res Ltd Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
MX2013001234A (es) 2010-08-05 2013-04-24 Conrig Pharma Aps Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
CN108434116B (zh) * 2017-02-16 2021-05-11 人福普克药业（武汉）有限公司 贝萨罗汀软胶囊及其制备方法
EP3651736B1 (en) 2017-07-14 2021-06-23 Janssen Pharmaceutica NV Long-acting formulations
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
TWI798452B (zh) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 隱形眼鏡產品
CN113018271B (zh) * 2019-12-25 2022-08-09 四川科瑞德制药股份有限公司 一种坦度螺酮药物组合物及其制备方法和用途
DK3861985T3 (da) 2020-02-06 2023-07-24 Ocular Therapeutix Inc Sammensætninger og fremgangsmåder til behandling af øjensygdomme
CN115768385A (zh) 2020-04-27 2023-03-07 视觉治疗股份有限公司 治疗过敏性结膜炎的方法
US20220105100A1 (en) * 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Safe brinzolamide and brimonidine compositions with enhanced benzalkonium chloride content
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
WO2024231938A1 (en) * 2023-05-11 2024-11-14 Akums Drugs & Pharmaceuticals Limited Benzalkonium chloride free ophthalmic formulation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5206267A (en) * 1991-05-09 1993-04-27 Morton Shulman Pain controlling composition and method of preparation
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5300287A (en) * 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
AU668447B2 (en) * 1993-04-16 1996-05-02 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
WO1996011672A1 (en) * 1994-10-13 1996-04-25 Wakamoto Pharmaceutical Co., Ltd. Lyophilized preparation providing reversibly thermogelling water-base medicinal composition
PT1190718E (pt) * 1996-12-13 2006-08-31 Alcon Lab Inc Composicoes oftalmicas contendo aminoalcoois
JPH10287552A (ja) * 1997-04-11 1998-10-27 Kobayashi Seiyaku Kogyo Kk 滅菌されたアシクロビル水性懸濁点眼剤及びその製造方法
JP3361106B2 (ja) 1997-07-29 2003-01-07 アルコン ラボラトリーズ，インコーポレイテッド ハードコンタクトレンズ・ケアのためのコンディショニング溶液
CA2383971A1 (en) * 1999-09-06 2001-03-15 Hiroaki Naka Prophylactic and therapeutic medicaments for ophthalmic diseases
BR0014203A (pt) 1999-09-24 2002-05-21 Alcon Inc Formulações de suspensão tópicas contendo ciprofloxacina e dexametasona
EP1282401A2 (en) * 2000-05-15 2003-02-12 PHARMACIA & UPJOHN S.p.A. Stabilized steroidal suspension
CA2412376A1 (en) * 2000-07-26 2002-01-31 Onkar N. Singh Pharmaceutical suspension compositions lacking a polymeric suspending agent
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
MXPA04002576A (es) * 2001-09-21 2004-06-18 Alcon Inc Metodo para tratar infecciones del oido medio.
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
WO2004000284A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
PL1638941T3 (pl) 2003-05-22 2010-11-30 Abbvie Bahamas Ltd Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz
US20050245497A1 (en) * 2004-04-08 2005-11-03 Penfold Philip L Treatment of ophthalmic conditions
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
BRPI0608774A2 (pt) 2005-05-10 2010-01-26 Alcon Inc composição de suspensão oftálmica aquosa topicamente administrável e uso da mesma
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
EP2120869A2 (en) * 2006-12-18 2009-11-25 Altus Pharmaceuticals Inc. Human growth hormone formulations
CN101687042A (zh) 2007-07-20 2010-03-31 爱尔康公司 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂
ES2429171T3 (es) 2007-12-19 2013-11-13 Sika Technology Ag Espuma polímera monocomponente que se endurece con la humedad
JP5155767B2 (ja) 2008-08-04 2013-03-06 国立大学法人大阪大学 ガス検知素子
BRPI1008920A2 (pt) 2009-03-03 2015-08-25 Alcon Res Ltd Composição farmacêutica para liberação de compostos inibidores de receptor de tirosina quinase (rtki) para o olho

Also Published As

Publication number Publication date
CA2745123A1 (en) 2010-06-10
US9707173B2 (en) 2017-07-18
DK2364137T3 (en) 2017-07-10
EP2364137A2 (en) 2011-09-14
AU2009322355B2 (en) 2015-11-05
AU2009322355A1 (en) 2010-06-10
HRP20170959T1 (hr) 2017-09-22
CY1119038T1 (el) 2018-01-10
EP2364137B1 (en) 2017-03-29
JP5661640B2 (ja) 2015-01-28
WO2010065730A3 (en) 2011-04-14
US20100144719A1 (en) 2010-06-10
PL2364137T3 (pl) 2017-09-29
HUE034662T2 (en) 2018-02-28
WO2010065730A2 (en) 2010-06-10
TW201023912A (en) 2010-07-01
JP2012511009A (ja) 2012-05-17
LT2364137T (lt) 2017-06-26
SI2364137T1 (sl) 2017-07-31
PT2364137T (pt) 2017-07-10
AR074423A1 (es) 2011-01-19
CA2745123C (en) 2018-11-13

Similar Documents

Publication Publication Date Title
ES2630037T3 (es) Suspensión farmacéutica
Tao et al. Injectable chitosan-based thermosensitive hydrogel/nanoparticle-loaded system for local delivery of vancomycin in the treatment of osteomyelitis
Vigani et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes
Ouyang et al. A facile and general method for synthesis of antibiotic-free protein-based hydrogel: Wound dressing for the eradication of drug-resistant bacteria and biofilms
Wang et al. Antibacterial effect of chitosan and its derivative on Enterococcus faecalis associated with endodontic infection
Chang et al. Liposomal dexamethasone–moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing
Geilich et al. Superparamagnetic iron oxide-encapsulating polymersome nanocarriers for biofilm eradication
Chaurasia et al. Nanomedicine approaches for corneal diseases
González-Sánchez et al. Silver nanoparticle based antibacterial methacrylate hydrogels potential for bone graft applications
Cassano et al. Gel-based materials for ophthalmic drug delivery
Khalil et al. Noninvasive biodegradable nanoparticles-in-nanofibers single-dose ocular insert: In vitro, ex vivo and in vivo evaluation
He et al. Development of an antimicrobial peptide-loaded mineralized collagen bone scaffold for infective bone defect repair
Wang et al. Dual-functional hybrid quaternized chitosan/Mg/alginate dressing with antibacterial and angiogenic potential for diabetic wound healing
Omolo et al. A hybrid of mPEG-b-PCL and G1-PEA dendrimer for enhancing delivery of antibiotics
Zhang et al. Efficient induction of antimicrobial activity with vancomycin nanoparticle-loaded poly (trimethylene carbonate) localized drug delivery system
Goncalves et al. Macrophage response to chitosan/poly-(γ-glutamic acid) nanoparticles carrying an anti-inflammatory drug
ES2637028T3 (es) Composiciones farmacéuticas que tienen biodisponibilidad deseable
Sahal et al. Electrospun essential oil-polycaprolactone nanofibers as antibiofilm surfaces against clinical Candida tropicalis isolates
CN117624172B (zh) 一种有机分子笼、有机分子笼纳米酶滴眼液及其制备方法
Cho et al. In‐vitro evaluation of a ciprofloxacin‐and ivacaftor‐coated sinus stent against Pseudomonas aeruginosa biofilms
Jia et al. Development of a Doxycycline Hydrochloride‐Loaded Electrospun Nanofibrous Membrane for GTR/GBR Applications
Huang et al. Physicochemical, antibacterial properties, and compatibility of ZnO-NP/chitosan/β-glycerophosphate composite hydrogels
Frisch et al. A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms
Fu et al. Synergistic and long-lasting wound dressings promote multidrug-resistant Staphylococcus aureus-infected wound healing
Xu et al. Tuning osteoporotic macrophage responses to favour regeneration by Cu-bearing titanium alloy in Porphyromonas gingivalis lipopolysaccharide-induced microenvironments